ArticleInternal medicine journal2026
Two decades of biologic and JAK inhibitor prescription patterns in the western region of Melbourne.
Article in Internal medicine journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimSafety concerns and medication shortages may influence prescribing practices in rheumatology. This study aimed to explore the impact of Janus kinase inhibitor (JAKi) safety warnings and the COVID-19 pandemic on biologic and targeted-synthetic disease-modifying antirheumatic drug (b/tsDMARD) prescription patterns from 2002 to 2024 in the western region of Melbourne.
methodsA retrospective audit was conducted on data from rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) patients who attended Western Health and Western Rheumatology clinics between 2002 and January 2024 inclusive. b/tsDMARD switching was analysed based on the first date of b/tsDMARD prescription using interrupted time series analysis, with ethics approval granted by the Western Health Office for Research (HREC/23/WH/101783).
resultsThere were 3124 new b/tsDMARD prescriptions. Following the 2021 United States JAKi boxed warning, the JAKi prescription rate decreased to -0.04/month (-0.20, 0.11) from 0.30/month (0.18, 0.42), P = 0.002. Supply shortages during the COVID-19 pandemic led to 44 b/tsDMARD switches. The most common cause of switching was inefficacy (32.6% of new prescriptions for AS, 42.6% for RA and 46.1% for PsA (P < 0.001)). Less than 5.4% of new prescriptions were from adverse events, underscoring b/tsDMARD safety.
conclusionsb/tsDMARD switches were primarily driven by inefficacy. Black box warning issuance led to decreased JAKi prescriptions. The COVID-19 pandemic led to minimal b/tsDMARD switches. Switching due to adverse events was infrequent, highlighting the overall safety of b/tsDMARDs in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.